PL
LLY icon

Pluribus Labs’s Eli Lilly LLY Stock Holding History

Pluribus Labs’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1.19M Buy
3,681
+2,219
+152% +$666K 2.18% 7
2022
Q1 		$419K Sell
1,462
-516
-26% -$133K 1.66% 15
2021
Q4 		$546K Buy
+1,978
New +$501K 0.58% 42

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pluribus Labs's LLY Position: Q2 2022 in Review

Pluribus Labs increased its Eli Lilly (LLY) stake by 152% in Q2 2022, buying an estimated $666K and bringing the position to 3,681 shares worth $1.19M. The position accounts for 2.18% of the portfolio, ranked #7.

Pluribus Labs first reported a position in LLY in Q4 2021 and has held it in 3 quarters since. 2,445 funds tracked by Wall St. Rank hold LLY as of Q2 2022.

  • Pluribus Labs held 3,681 shares of Eli Lilly worth $1.19M as of Q2 2022.
  • Pluribus Labs bought 2,219 Eli Lilly shares in Q2 2022, an estimated $666K.
  • Eli Lilly made up 2.18% of Pluribus Labs's portfolio in Q2 2022, its #7 holding.
  • Pluribus Labs first reported a position in Eli Lilly in Q4 2021 and has held it in 3 quarters since.
  • 2,445 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2022.

Based on Pluribus Labs's 13F filing for Q2 2022, filed 12 Aug 2022.